Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.24 - Poster Session 1 - Clinical Care
- Type: Poster Session
- Track: Supportive Care
- Presentations: 53
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.24-008 - Are patients' needs being met after-hours? An evaluation of phone calls made after hours for patients with thoracic malignancies.
09:30 - 09:30 | Author(s): M.I. Patel
- Abstract
Loading... -
+
P1.24-048 - Stage 1 results of a 2-stage phase II trial of single agent amrubicin in patients with previously treated thymic malignancies
09:30 - 09:30 | Author(s): H.A. Wakelee
- Abstract
Loading...
-
+
MO03 - Thymic Malignancies
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 11
- Moderators:F. Detterbeck
- Coordinates: 10/28/2013, 10:30 - 12:00, Bayside Gallery B, Level 1
-
+
MO03.08 - Increased Galectin-1 Expression in a Thymic Epithelial Tumor Tissue Microarray (TMA) and Galectin-1 Knockdown Studies in a Thymoma Cell Line
11:15 - 11:20 | Author(s): J.W. Riess
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MO03.11 - DISCUSSANT
11:30 - 11:45 | Author(s): H.A. Wakelee
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MS03 - The Cutting Edge of Molecularly Targeted Therapy
- Type: Mini Symposia
- Track: Medical Oncology
- Presentations: 4
- Moderators:N. Saijo
- Coordinates: 10/28/2013, 14:00 - 15:30, Plenary Hall, Ground Level
-
+
MS03.0 - N/A - Chair Intro
14:00 - 14:05
- Abstract
No abstract available for this presentation
-
+
MS03.1 - Novel Targets in Small Cell Cancer
14:05 - 14:30 | Author(s): R. Thomas
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS03.2 - Novel Targets in Squamous Cancer
14:30 - 14:55 | Author(s): P. Hammerman
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
MS03.3 - Novel Targets in Adenocarcinoma
14:55 - 15:20 | Author(s): M. Meyerson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.15 - Poster Session 2 - Thymoma
- Type: Poster Session
- Track: Thymoma & Other Thoracic Malignancies
- Presentations: 8
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.15-003 - Gli1, Notch1 and CTNNB1 Expression by Automated Quantitative Immunofluorescence (AQUA) in a Thymic Malignancy Tissue Microarray (TMA)
09:30 - 09:30 | Author(s): J.W. Riess
- Abstract
Loading...
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.01 - Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy
10:30 - 10:40 | Author(s): M. Reck
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.02 - Efficacy of standard care for second-line advanced non-small cell lung cancer (NSCLC) by KRAS mutation status: observations on MEK inhibitor enhancement of chemotherapy
10:40 - 10:50 | Author(s): P.A. Jänne
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.03 - Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial
10:50 - 11:00 | Author(s): A. Vergnenegre
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.04 - DISCUSSANT
11:00 - 11:15 | Author(s): J.C. Yang
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.05 - Efficacy, safety, and patient-reported outcomes (PROs) with crizotinib versus chemotherapy in Asian patients in a phase III study of previously treated advanced ALK-positive non-small cell lung cancer (NSCLC)
11:15 - 11:25 | Author(s): M. Nishio
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.06 - A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK+ Non-Small Cell Lung Cancer (NSCLC) patients who have failed crizotinib (AF-002JG/NP28761, NCT01588028).
11:25 - 11:35 | Author(s): S. Gadgeel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.07 - Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028).
11:35 - 11:45 | Author(s): S.I. Ou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
O16.08 - DISCUSSANT
11:45 - 12:00 | Author(s): D..R. Camidge
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
O18 - Cancer Control and Epidemiology II
- Type: Oral Abstract Session
- Track: Prevention & Epidemiology
- Presentations: 8
- Moderators:M.R. Spitz
- Coordinates: 10/29/2013, 10:30 - 12:00, Bayside 103, Level 1
-
+
O18.06 - Vietnamese non-small cell lung cancer patients in California: molecular profiles and clinical characteristics
11:25 - 11:35 | Author(s): K.H. Nguyen
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.01 - Poster Session 3 - Cancer Biology
- Type: Poster Session
- Track: Biology
- Presentations: 21
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.01-007 - Energy metabolism in lung adenocarcinoma
09:30 - 09:30 | Author(s): C. Hoang
- Abstract
Loading...
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-003 - Correlative Analysis of Circulating Biomarkers from a Phase 1b/2 trial of Cabozantinib (C) with or without Erlotinib (E) in Patients (Pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): S.K. Padda
- Abstract
Loading...
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-006 - Erlotinib (E) and Dovitinib (TKI258) (D) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC): A Significant Pharmacokinetic (PK) Interaction
09:30 - 09:30 | Author(s): M. Das
- Abstract
Loading...
-
+
P3.22 - Poster Session 3 - Epidemiology, Etiology
- Type: Poster Session
- Track: Prevention & Epidemiology
- Presentations: 10
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.22-008 - Are there disparities in lung cancer incidence trends among Hispanics and African Americans? An analysis of the Surveillance Epidemiology and End Results Database 1992-2010
09:30 - 09:30 | Author(s): M.I. Patel
- Abstract
Loading...
